Future Perspectives in the Medical Treatment of Endometriosis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
UNLABELLED: In the last few years, our understanding of the pathogenesis of endometriosis at the cellular and molecular levels has improved significantly. This may give us the opportunity to use new, specific agents for the treatment of this disorder. Despite the effectiveness of the available treatments, novel therapeutic strategies may improve our ability to eliminate endometriotic lesions when present and to prevent the recurrence of endometriosis after surgical treatment. This review focuses on the new, experimental approaches to the medical treatment of endometriosis and its symptoms. The blockage of aromatase activity in endometriotic lesions with an aromatase inhibitor may represent a new step in the medical treatment of endometriosis. Preliminary clinical studies have demonstrated the efficacy of third-generation nonsteroidal aromatase inhibitors (ie, anastrozole and letrozole) in reducing the intensity of pain symptoms associated with the presence of endometriosis. The new selective progesterone receptor modulators may represent a valid hormonal treatment option. Therapeutic manipulation of the immune system through TNFalpha inhibitors may be beneficial in women with endometriosis. New pharmaceutical agents affecting inflammation, angiogenesis, and matrix metalloproteinase activity may prevent or inhibit the development of endometriosis. Further clinical trials may determine if these new therapies are superior to current medical treatment strategies for endometriosis. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians Learning. OBJECTIVES: After completion of this article, the reader should be able to describe the new experimental medical treatments of endometriosis, state that the clinical use of nonsteroidal aromatase inhibitors for endometriosis appears to be efficacious but is based on preliminary clinical data, and recall that the drugs used for endometriosis in the future may include manipulation of the immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Aromatase expression in endometriosis.
Noble, L. S., Simpson, E. R., Johns, A., & Bulun, S. E. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550748 · Cited by 566 · cited 1×
“Noble et al (4) demonstrated that endometriotic lesions contain aromatase P-450 and, as a consequence, can produce estrogens (5).”
BackgroundTreatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270
Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis
Rana, N., Braun, D. P., House, R., Gebel, H., Rotman, C., & Dmowski, W. P. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58262-4 · Cited by 264
Soysal, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh035 · Cited by 227 · cited 1×
“Recently, in a prospective, randomized trial, Soysal et al (13) demonstrated that 6 months of treatment with anastrozole (1 mg/day) and goserelin as compared with goserelin alone increased the pain-free interval and decreased symptom recurrence rates in patients after surgery for severe endometriosis.”
BackgroundTreatment of endometriosis with the antiprogesterone mifepristone (RU486)
Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58022-4 · Cited by 216
Kettel, L. M., Murphy, A. A., Mortola, J. F., Liu, J. H., Ulmann, A., & Yen, S. S. C. (1991) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54531-2 · Cited by 151
Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue
Fang, Z., Yang, S., Gurates, B., Tamura, M., Simpson, E., Evans, D., & Bulun, S. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8683 · Cited by 91 · cited 1×
“In line with these observations, Fang et al (9) showed that both an intact P-450 gene and the presence of aromatase enzyme activity are essential for the growth of ectopic uterine tissue in a mouse model of endometriosis.”
Result
Cited by
Endometriosis: Current Therapies and New Pharmacological Developments
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009) · Drugs · doi:10.2165/00003495-200969060-00002 · Cited by 182
Walch, K., Unfried, G., Huber, J., Kurz, C., van Trotsenburg, M., Pernicka, E., & Wenzl, R. (2009) · Contraception · doi:10.1016/j.contraception.2008.07.017 · Cited by 128
Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review
Ferrero, S., Gillott, D. J., Venturini, P. L., & Remorgida, V. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-89 · Cited by 109
“Based on the molecular observations of increased expression of aromatase P450 in endometriotic tissue published over the last ten years, some authors used aromatase inhibitors (AIs) to treat pain symptoms in premenopausal women with endometriosis [17,18].”
BackgroundSelf-citationLetrozole and desogestrel‐only contraceptive pill for the treatment of stage IV endometriosis
REMORGIDA, V., ABBAMONTE, L. H., RAGNI, N., FULCHERI, E., & FERRERO, S. (2007) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2007.00722.x · Cited by 83
Self-citationEndometriosis-associated nerve fibers and pain.
MEDINA, M. G., & LEBOVIC, D. I. (2009) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1080/00016340903176826 · Cited by 63
“A significant amount of research has demonstrated the capability of current hormonal treatments to diminish the reported pain associated with endometriosis symptoms (21,22).”
Background
Metadata
- Authors
- Ferrero, S., Abbamonte, L. H., Anserini, P., Remorgida, V., & Ragni, N.
- Venue
- Obstetrical & Gynecological Survey
- Published
- 2005-12
- Volume
- 60
- Issue
- 12
- Pages
- 817-826
- ISSN
- 0029-7828 (ISSN-L)
- OpenAlex
- W2081540072
- Cited by
- 57
- References
- 8
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Future Perspectives in the Medical Treatment of Endometriosis. https://app.cochat.ai/papers/10.1097/01.ogx.0000189153.87365.dc
- The paper
- Ferrero, S., Abbamonte, L. H., Anserini, P., Remorgida, V., & Ragni, N. (2005). Future Perspectives in the Medical Treatment of Endometriosis. Obstetrical & Gynecological Survey. https://doi.org/10.1097/01.ogx.0000189153.87365.dc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.